JP2019512242A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512242A5 JP2019512242A5 JP2018548050A JP2018548050A JP2019512242A5 JP 2019512242 A5 JP2019512242 A5 JP 2019512242A5 JP 2018548050 A JP2018548050 A JP 2018548050A JP 2018548050 A JP2018548050 A JP 2018548050A JP 2019512242 A5 JP2019512242 A5 JP 2019512242A5
- Authority
- JP
- Japan
- Prior art keywords
- tcr
- seq
- chain
- alpha
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 229960002685 biotin Drugs 0.000 claims 2
- 235000020958 biotin Nutrition 0.000 claims 2
- 239000011616 biotin Substances 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 201000007487 gallbladder carcinoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662308970P | 2016-03-16 | 2016-03-16 | |
| GB1604494.3 | 2016-03-16 | ||
| GBGB1604494.3A GB201604494D0 (en) | 2016-03-16 | 2016-03-16 | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
| US62/308,970 | 2016-03-16 | ||
| PCT/EP2017/056289 WO2017158116A1 (en) | 2016-03-16 | 2017-03-16 | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512242A JP2019512242A (ja) | 2019-05-16 |
| JP2019512242A5 true JP2019512242A5 (OSRAM) | 2019-06-20 |
| JP6929867B2 JP6929867B2 (ja) | 2021-09-01 |
Family
ID=55952419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548050A Expired - Fee Related JP6929867B2 (ja) | 2016-03-16 | 2017-03-16 | がんに対する免疫療法で使用するための形質移入ｔ細胞およびｔ細胞受容体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10537624B2 (OSRAM) |
| EP (1) | EP3430037B1 (OSRAM) |
| JP (1) | JP6929867B2 (OSRAM) |
| KR (1) | KR102266721B1 (OSRAM) |
| CN (1) | CN108884143A (OSRAM) |
| AU (1) | AU2017235069B2 (OSRAM) |
| BR (1) | BR112018067989A2 (OSRAM) |
| CA (1) | CA3017419A1 (OSRAM) |
| CR (1) | CR20180490A (OSRAM) |
| EA (1) | EA201891759A1 (OSRAM) |
| GB (1) | GB201604494D0 (OSRAM) |
| MA (2) | MA43328B2 (OSRAM) |
| MX (1) | MX2018011223A (OSRAM) |
| PE (1) | PE20190124A1 (OSRAM) |
| SG (1) | SG11201807590SA (OSRAM) |
| TW (1) | TWI788284B (OSRAM) |
| UA (1) | UA124532C2 (OSRAM) |
| WO (1) | WO2017158116A1 (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS63727B1 (sr) * | 2016-03-16 | 2022-12-30 | Immatics Biotechnologies Gmbh | Transficirane t ćelije i t-ćelijski receptori za upotrebu u imunoterapiji protiv malignih tumora |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| TW201835100A (zh) * | 2017-02-06 | 2018-10-01 | 國立研究開發法人國立癌症研究中心 | 新穎ｔ細胞受體 |
| EP3692063A1 (en) | 2017-10-03 | 2020-08-12 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
| KR102828999B1 (ko) | 2018-02-11 | 2025-07-04 | 메모리얼 슬로안 케터링 캔서 센터 | 비-hla 제한된 t 세포 수용체 및 이의 용도 |
| US20200405762A1 (en) * | 2018-02-12 | 2020-12-31 | Fred Hutchinson Cancer Research Center | Cyclin a1 specific t cell receptors and uses thereof |
| US12331095B2 (en) | 2018-03-14 | 2025-06-17 | Medigene Immunotherapies Gmbh | Inducible T cell receptors and uses thereof |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| KR102764123B1 (ko) * | 2018-04-05 | 2025-02-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | Τ 세포 수용체 및 이를 발현하는 조작된 세포 |
| JP7505785B2 (ja) | 2018-09-21 | 2024-06-25 | エックスライフエスシー リミテッド | Ａｆｐ抗原を識別する高親和性ｔ細胞受容体 |
| US12179037B2 (en) | 2018-12-11 | 2024-12-31 | Board Of Regents, The University Of Texas System | Radiotherapies and uses thereof |
| CA3123352A1 (en) | 2018-12-20 | 2020-06-25 | Ava Lifescience Gmbh | Method for selecting biological binding molecules |
| DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| KR20220029584A (ko) | 2019-05-27 | 2022-03-08 | 이매틱스 유에스 인코포레이티드 | 바이러스 벡터 및 입양 세포 요법에서 그 사용 |
| EP3986450A4 (en) * | 2019-06-20 | 2023-06-28 | Memorial Sloan Kettering Cancer Center | T cell receptors targeting pik3ca mutations and uses thereof |
| CN110357953B (zh) * | 2019-07-17 | 2022-05-03 | 深圳市因诺转化医学研究院 | 识别人巨细胞病毒pp65抗原的TCR |
| US20220288118A1 (en) * | 2019-07-31 | 2022-09-15 | Forty Seven, Inc. | Depletion regimes for engineered t-cell or nk-cell therapy |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| CA3154287A1 (en) * | 2019-09-12 | 2021-03-18 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| JP2023515131A (ja) | 2020-02-24 | 2023-04-12 | イマティクス ユーエス，アイエヌシー． | がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法 |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス，アイエヌシー． | Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法 |
| DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
| MX2023012899A (es) | 2021-05-05 | 2023-11-08 | Immatics Biotechnologies Gmbh | Polipeptidos de union a antigeno bma031 mejorados. |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| AU2023262596A1 (en) | 2022-04-28 | 2024-12-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101287831B (zh) | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| DK2172211T3 (en) | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| AU2014271235B2 (en) * | 2008-10-01 | 2017-03-02 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including neuronal and brain tumors |
| TW201124530A (en) * | 2009-12-01 | 2011-07-16 | Oncotherapy Science Inc | IMP-3 oligopeptides and vaccines including the same |
| SI2895509T1 (sl) * | 2012-09-14 | 2020-04-30 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services, Office Of Technology Transfer, National Institutes Of Health | T-celični receptorji, ki prepoznajo MAGE-A3, omejen na MHC razreda II |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
-
2016
- 2016-03-16 GB GBGB1604494.3A patent/GB201604494D0/en not_active Ceased
-
2017
- 2017-03-16 JP JP2018548050A patent/JP6929867B2/ja not_active Expired - Fee Related
- 2017-03-16 UA UAA201809121A patent/UA124532C2/uk unknown
- 2017-03-16 PE PE2018001777A patent/PE20190124A1/es unknown
- 2017-03-16 SG SG11201807590SA patent/SG11201807590SA/en unknown
- 2017-03-16 CN CN201780017419.XA patent/CN108884143A/zh active Pending
- 2017-03-16 MA MA43328A patent/MA43328B2/fr unknown
- 2017-03-16 CR CR20180490A patent/CR20180490A/es unknown
- 2017-03-16 MX MX2018011223A patent/MX2018011223A/es unknown
- 2017-03-16 CA CA3017419A patent/CA3017419A1/en not_active Abandoned
- 2017-03-16 KR KR1020187029658A patent/KR102266721B1/ko not_active Expired - Fee Related
- 2017-03-16 EA EA201891759A patent/EA201891759A1/ru unknown
- 2017-03-16 TW TW106108697A patent/TWI788284B/zh not_active IP Right Cessation
- 2017-03-16 BR BR112018067989A patent/BR112018067989A2/pt not_active IP Right Cessation
- 2017-03-16 MA MA45309A patent/MA45309B1/fr unknown
- 2017-03-16 WO PCT/EP2017/056289 patent/WO2017158116A1/en not_active Ceased
- 2017-03-16 EP EP17710963.4A patent/EP3430037B1/en active Active
- 2017-03-16 US US15/461,020 patent/US10537624B2/en active Active
- 2017-03-16 AU AU2017235069A patent/AU2017235069B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512242A5 (OSRAM) | ||
| JP2020511936A5 (OSRAM) | ||
| US11945854B2 (en) | Transfected T-cells and T-cell receptors for use in immunotherapy against cancers | |
| US20220235113A1 (en) | TCR Libraries | |
| JP2020500523A5 (OSRAM) | ||
| EP3430030B1 (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| JP7720685B2 (ja) | Ｔ細胞レセプター | |
| FI3688027T3 (fi) | Mutatoidun p53:n tunnistavia t-solureseptoreita | |
| JP2014528714A5 (OSRAM) | ||
| HRP20220131T1 (hr) | Nova terapija s t-staničnim receptorima i imunološka terapija koja koristi iste | |
| FI3946621T3 (fi) | Mage a4 -t-solureptoreja | |
| CA3056261A1 (en) | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods | |
| JP2015506945A5 (OSRAM) | ||
| HRP20190472T1 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
| JP2012531212A5 (OSRAM) | ||
| CA3001264A1 (en) | Pd-l1 binding polypeptide | |
| JP2018512145A5 (OSRAM) | ||
| JP2013529070A5 (OSRAM) | ||
| JP2016196468A5 (OSRAM) | ||
| JP2008532523A5 (OSRAM) | ||
| JP2012100677A5 (OSRAM) | ||
| JP2014500002A5 (OSRAM) | ||
| HRP20221375T1 (hr) | Transfecirane t-stanice i t-stanični receptori za upotrebu u imunoterapiji protiv raka | |
| WO2017072273A1 (en) | New polypeptide | |
| JP2013534515A5 (ja) | 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体 |